(Tables to follow)GenVec, Inc.Condensed Statements of Operations(in thousands, except per share data)Quarter EndedYear Ended12/31/1112/31/1012/31/1112/31/10(unaudited)Revenues
$3,389$5,191$17,744$16,467Operating expenses:Research and development
3,8784,92017,41620,936General and administrative
2,0231,5267,8108,152Total operating expenses
(2,512)(1,255)(7,482)(12,621)Other income:Interest income, net
12441213Total other income, net
$(2,504)$(1,004)$(7,441)$(12,274)Basic and diluted net loss per share
$(0.19)$(0.08)$(0.58)$(0.97)Shares used in computation of basicand diluted net loss per share
12,93412,90812,92112,671GenVec, Inc.Selected Balance Sheet Information(in thousands)As of December 31,20112010Cash, cash equivalents and short-term investments$26,446$35,170Working capital25,73931,689Total assets29,86639,432Stockholders' equity26,53832,420Retail Investor and Media Contact:Institutional Investor Contact:GenVec, Inc.
S.A. Noonan CommunicationsDouglas J. Swirsky
Susan A. Noonan(240) 632-5510
|SOURCE GenVec, Inc.|
Copyright©2010 PR Newswire.
All rights reserved